Madison, WI, June 16, 2020 — Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the appointment of Terry Brady as Chief Financial Officer.
Brady is a seasoned executive with broad experience leading financial departments and an extensive background in leading operations to support scientific innovation. Brady will be responsible for all aspects of establishing and scaling the financial and operating infrastructure of the company.
"We are excited to announce this critical addition to the leadership team," said Maneesh Arora, founder and CEO of Elephas. "Terry’s strong business and accounting background, coupled with his two decades of experience, will be a crucial asset as we build and scale the company”.
A licensed CPA, Brady started his career at KMPG before joining Silverman Consulting and becoming a partner. After leaving Silverman, Brady joined Freedom Graphic System as the Chief Financial Officer. Most recently, he served as the Chief Financial Officer at Farcast Biosciences, a venture-backed oncology diagnostics company.
"While many therapies have been approved to combat the consistent rise in cancer, clinicians still do not have a way to predict with confidence which treatment is best for their patients,” said Brady. "Solving that dilemma and providing better outcomes for cancer patients is at the heart of Elephas’ mission, and that is why I could not be more excited to join this team.”
Brady earned his bachelor’s and master’s degrees in accounting from the University of Notre Dame and an MBA in management, strategy, and operations from Northwestern University – Kellogg School of Management.
About Elephas
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle the massive oncology dilemma, Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
Contact
John Fitzpatrick
marketing@elephas.com
